WH-4-023
(Synonyms: Dual LCK/SRC inhibitor) 目录号 : GC13600An inhibitor of Lck and Src
Cas No.:837422-57-8
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Kinase experiment[1]: | |
Lck kinase assays |
To determine the inhibitory activity of WH-4-023 against Lck, kinase assays were conducted. The Lck HTRF kinase assay involved ATP-dependent phosphorylation of a biotinylated substrate peptide of gastrin with or without WH-4-023. The final concentration of ATP, gastrin and Lck were 0.5 μM, 1.2 μM and 250 pM, respectively. Buffer were made up as follows: 50 mM HEPES pH=7.5, 2 mM DTT, 5 mM MnCl2, 20 mM MgCl2, 50 mM NaCl, 0.05% BSA. The reaction was quenched and ended by adding 160 μL detection reagent. Detection reagent was prepared as follows: 50 mM Tris, pH=7.5, 3 mM EDTA, 100 mM NaCl, 0.05% BSA, 0.1% Tween-20. Before reading, streptavidin allophycocyanin and anti-phosphotyrosine Ab were added at a final concentration of 0.4 μg/mL and 0.025 nM, respectively. Assay plate was read with excitation at 320 nm and emission at 615 and 655 nm. |
Cell experiment[2]: | |
Cell lines |
Naive human pluripotent cells |
Preparation method |
The solubility of this compound in DMSO is > 10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
Reacting condition |
1 μM |
Applications |
WH-4-023 is a potent and selective Src and Lck inhibitor with IC50 values of 6 and 2 nM, respectively[1].Naive human pluripotent cells were maintained in media containing WH-4-023. WH-4-023 improves the fraction of viable GFP+ cells. Withdrawal of the WH-4-023 results in a change in morphology and slight decrease of OCT4-DPE-GFP reporter activity[2]. |
References: [1]. Martin M W, Newcomb J, Nunes J J, et al. Novel 2-aminopyrimidine carbamates as potent and orally active inhibitors of Lck: synthesis, SAR, and in vivo antiinflammatory activity[J]. Journal of medicinal chemistry, 2006, 49(16): 4981. [2]. Theunissen T W, Powell B E, Wang H, et al. Systematic Identification of Defined Conditions for Induction and Maintenance of Naive Human Pluripotency[J]. Cell stem cell, 2014, 15(4): 471. |
WH-4-023 is a potent and selective Lck and Src inhibitor with IC50 values of 2 and 6 nM, respectively [1]. It is also an inhibitor of IC50 values of 10, 22 and 60 nM for SIK 1, 2 and 3, respectively [2].
Lck and Src are cytoplasmic tyrosine kinases of the Src family expressed in T cells and NK cells [1]. SIKs restrict the formation of regulatory macrophages and that their inhibition greatly stimulates the production of IL-10 and other anti-inflammatory molecules [2].
WH-4-023 inhibited a number of protein tyrosine kinases that possess a Thr residue at the gatekeeper site, such as FGF and Ephrin receptors, Src family members (Src, Lck, and Yes) and BTK. WH-4-023 also inhibited the SIKs and did not inhibit any other member of the AMPK-related kinase subfamily, which all possess a large hydrophobic residue (Met or Leu) at the gatekeeper site. WH-4-023 inhibited SIK 1, 2 and 3 with IC50 values of 10, 22 and 60 nM, respectively. Also, WH-4-023 increased LPS-stimulated IL-10 production and greatly suppressed proinflammatory cytokine secretion [2].
References:
[1]. Martin MW, Newcomb J, Nunes JJ, et al. Novel 2-aminopyrimidine carbamates as potent and orally active inhibitors of Lck: synthesis, SAR, and in vivo antiinflammatory activity. J Med Chem, 2006, 49(16): 4981-4991.
[2]. Clark K, MacKenzie KF, Petkevicius K, et al. Phosphorylation of CRTC3 by the salt-inducible kinases controls the interconversion of classically activated and regulatory macrophages. Proc Natl Acad Sci U S A, 2012, 109(42): 16986-16991.
Cas No. | 837422-57-8 | SDF | |
别名 | Dual LCK/SRC inhibitor | ||
化学名 | 2,6-dimethylphenyl (2,4-dimethoxyphenyl)(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)carbamate | ||
Canonical SMILES | CN1CCN(C2=CC=C(NC3=NC(N(C4=CC=C(OC)C=C4OC)C(OC5=C(C)C=CC=C5C)=O)=CC=N3)C=C2)CC1 | ||
分子式 | C32H36N6O4 | 分子量 | 568.67 |
溶解度 | ≥ 56.9mg/mL in DMSO | 储存条件 | Desiccate at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.7585 mL | 8.7924 mL | 17.5849 mL |
5 mM | 0.3517 mL | 1.7585 mL | 3.517 mL |
10 mM | 0.1758 mL | 0.8792 mL | 1.7585 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。